Unknown Author
January 23, 2026
Latham & Watkins Advises on UroGen’s US$120 Million Private Placement of Ordinary Shares
1 min
AI-made summary
- UroGen Pharma Ltd
- has entered into a definitive securities purchase agreement for a private placement with selected institutional and accredited investors, expecting to raise approximately US$120 million in gross proceeds before commissions and expenses
- Latham & Watkins LLP represented the placement agents, with a team led by New York partner Nathan Ajiashvili and London/Tel Aviv counsel Michael Rosenberg, along with New York associates Sandy Kugbei and Alex Gulino.
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, has announced that it has entered into a definitive securities purchase agreement in connection with a private placement to selected institutional and accredited investors. UroGen expects to receive gross proceeds of approximately US$120 million, before deducting placement agent commissions and other offering expenses. Latham & Watkins LLP represented the placement agents in the transaction with a capital markets team led by New York partner Nathan Ajiashvili and London/Tel Aviv counsel Michael Rosenberg, with New York associates Sandy Kugbei and Alex Gulino.~~
Article Author
Unknown Author
The Sponsor